Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study

WALTHAM, Mass., May 25, 2023 -- Apellis Pharmaceuticals, Inc. today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral... | May 25, 2023

Related Keywords

Australia , Saudi Arabia , Canada , United States , Jeffrey Eisele , Meredith Kaya , Lissa Pavluk , National Institute Of Neurological Disorders , Linkedin , Twitter , Nasdaq , Exchange Commission On , Apellis Pharmaceuticals Inc , European Union , Exchange Commission , Combined Assessment , Amyotrophic Lateral Sclerosis , United Kingdom , Forward Looking Statement , Private Securities Litigation Reform Act , Apelli Annual Report , National Institute , Neurological Disorders , Amyotrophic Lateral Sclerosis Fact , Retrieved June , Apellis Pharmaceuticals , Nc Stock Exchange , News , Information , Press Release , Bay , 023 , Apellis , Oday , Nnounced , Hat , The , Hase , , Eridian , Study , Nvestigating , Systemic , Pegcetacoplan , Or , Treatment , F , Myotrophic Apls Us03753u1060 ,